Valeant
FREE Daily Email Newsletter
Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors
May 16, 2013 7:56 am | News | CommentsValeant Pharmaceuticals International, Inc. announced that Dr. Laurence Paul has resigned from Valeant's Board of Directors due to expanded business, philanthropic, and personal commitments. Dr. Paul was originally elected to Biovail Corporation's Board of Directors in June 2002 where he served in several capacities.
Actavis Buys Vaginal Gel from Valeant for $55M
May 1, 2013 1:40 pm | by The Associated Press | News | CommentsActavis Inc. said Wednesday it acquired a bacterial vaginosis gel developed by Valeant Pharmaceuticals International Inc. Actavis said it agreed to pay Valeant $55 million for its metronidazole gel product, which has not yet received marketing approval. The total includes both an upfront payment...
Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana and Zyclara
April 10, 2013 8:11 am | News | CommentsActavis and Valeant Pharmaceuticals today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant, resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application for Clindamycin and Tretinoin Gel, a generic version of Ziana, as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara.
Merz Pharma Withdraws Obagi Acquisition Offer
April 8, 2013 10:05 am | by The Associated Press | News | CommentsGerman drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker. Merz said Monday it is a "disciplined buyer," and it was withdrawing its $22-per-share cash bid for Obagi after Canadian drugmaker Valeant Pharmaceuticals raised its offer last week to $24 per share.
Valeant Says Generic Approval Could Lower Profit
April 4, 2013 9:58 am | by The Associated Press | News | CommentsValeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year. Mylan Inc. on Wednesday received final approval from the U.S. Food and Drug Administration to sell the first generic version of...
Valeant Pharmaceuticals and Obagi Medical Products Agree on an Increased Offer Price
April 3, 2013 8:12 am | News | CommentsValeant Pharmaceuticals International, Inc. today announced that Valeant and Obagi Medical Products, Inc. have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.
Merz Pharma Offers to Buy Obagi for About $383.5M
April 3, 2013 8:04 am | News | CommentsGerman drugmaker Merz Pharma Group said Tuesday that it wants to buy dermatology products maker Obagi for about $383.5 million, toping an offer made by Canada's Valeant Pharmaceuticals last month. Merz said it sent a letter to Obagi Medical Products Inc.'s board offering to buy all of the company's stock for $22 per share.
Valeant Pharma Posts 4Q Loss on Deal-Related Costs
February 28, 2013 8:26 am | by The Associated Press | News | CommentsValeant Pharmaceuticals International Inc. reported a fourth-quarter loss, as acquisition-related costs countered steep revenue growth for the Canadian drugmaker. Valeant focuses on dermatology, neurology and branded generics. Its products include the antidepressant Wellbutrin XL and the blood...
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin from Eisai
February 21, 2013 8:10 am | News | CommentsEisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. announced today that Valeant has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones
Valeant Pharmaceuticals and Galderma Agree on Revised Agreement Terms
December 6, 2012 3:10 am | News | CommentsValeant Pharmaceuticals International, Inc. has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A.
Valeant Pharmaceuticals Announces New Management Appointments
November 28, 2012 3:12 am | News | CommentsValeant Pharmaceuticals International, Inc. announced today that Ryan Weldon and Jason Hanson will be named to Valeant's Executive Management Team.
Valeant Pharmaceuticals Announces Management Change
September 14, 2012 4:07 am | News | CommentsValeant Pharmaceuticals has announced that Rajiv De Silva, Valeant's President and Chief Operating Officer of Specialty Pharmaceuticals, will be leaving the company to pursue other interests.
Valeant Pharmaceuticals to Acquire OraPharma
June 15, 2012 4:20 am | News | CommentsValeant Pharmaceuticals International, Inc. announced today that Valeant has agreed to acquire OraPharma, a specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners.
Valeant Pharmaceuticals to Go for Targets Not in the 'Bulls Eye' of Big Pharma
May 31, 2012 4:13 am | by LuAnn LaSalle, THE CANADIAN PRESS | News | CommentsMONTREAL — Valeant Pharmaceuticals International Inc. expects to grow in emerging and niche markets that aren't being eyed by "big pharma," chief executive officer Michael Pearson said Wednesday.
Valeant Pharmaceuticals to Acquire Certain Assets from Swiss Herbal
May 24, 2012 7:57 am | News | CommentsValeant Pharmaceuticals International, Inc. announced today that it has agreed to acquire certain assets from Swiss Herbal Remedies Limited, a nutraceutical company that manufactures and markets a broad range of scientifically formulated vitamins, minerals and supplements, for less than one times sales.
Valeant Pharmaceuticals to Acquire Certain Assets from Atlantis Pharma in Mexico
April 18, 2012 4:11 am | News | CommentsValeant Pharmaceuticals International, Inc. announced today that Valeant has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company located in Mexico with a broad product portfolio, including products in the gastro, analgesics and anti-inflammatory therapeutic categories, for approximately $71 million.
Valeant Pharmaceuticals Acquires Pedinol
April 12, 2012 4:21 am | News | CommentsValeant Pharmaceuticals International, Inc. announced today that the company has acquired Pedinol Pharmacal, Inc., a podiatry-focused, privately-owned specialty pharmaceutical company based in the U.S., for less than 1.5 times sales.
Valeant Buys Products from Gerot Lannach
March 13, 2012 8:17 am | by The Associated Press | News | CommentsValeant Pharmaceuticals International Inc. said Tuesday that it is buying a generic aspirin and other products from Austrian generic drugmaker Gerot Lannach as part of a push to expand in Eastern Europe.
Valeant Pharmaceuticals Acquires Minority Investment in Brazilian Biotech Company
March 12, 2012 4:11 am | News | CommentsValeant Pharmaceuticals International, Inc. announced today that the company has acquired a 19.9% minority equity investment in Pele Nova Biotecnologia S.A. a Brazilian research company focused on tissue regeneration.
Valeant Pharmaceuticals to Acquire Eyetech
February 13, 2012 3:45 am | News | CommentsValeant Pharmaceuticals has agreed to acquire Eyetech Inc., a privately-owned ophthalmic biotechnology company dedicated to the treatment of sight-threatening diseases of the retina, for an upfront payment and potential future milestones that total significantly less than two times sales.
Valeant Completes Divestiture of Generic Dermatology Products to Mylan
February 6, 2012 3:12 am | News | CommentsValeant Pharmaceuticals International, Inc. today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc.
Valeant Pharmaceuticals Withdraws Offer for Acquisition of ISTA Pharmaceuticals Inc.
January 30, 2012 3:15 am | News | CommentsValeant Pharmaceuticals International, Inc. today announced that it has withdrawn its offer to acquire ISTA Pharmaceuticals Inc. for $7.50 per share in cash.
Valeant Raises Offer for ISTA Pharmaceuticals
January 17, 2012 3:21 am | News | CommentsISTA Pharmaceuticals announced today that it has received a revised non-binding proposal from Valeant Pharmaceuticals to acquire ISTA and will consider the updated proposal as part of its ongoing review of strategic options.
Valeant Pharmaceuticals Expects to Find $200M in Savings in 2012
January 9, 2012 3:28 am | by Sunny Freeman, The Canadian Press | News | CommentsTORONTO — Valeant Pharmaceuticals expects to find $200M of cost savings this year as it works to fully incorporate drug companies acquired in a nearly $3-billion buying spree since merging with Biovail.
Valeant Completes Acquisition of Dermik
December 19, 2011 3:39 am | News | CommentsValeant Pharmaceuticals International, Inc. announced that effective December 16, 2011, the company completed its previously announced acquisition of Dermik, a dermatology unit of Sanofi.
